Updated Results of the Idecabtagene Vicleucel (ide-cel bb2121) CRB-401 Trial in Relapsed Refractory Multiple Myeloma (https://www.myeloma.org/videos/updated-results-idecabtagene-vicleucel-ide-cel-bb2121-crb-401-trial-relapsed-refractory)
What is the purpose of this study?
The phase 1 study will explore the use of this B-cell maturation antigen (BCMA)–directed CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) in patients with high-risk newly diagnosed multiple myeloma.
In this video:
Dr. Yi Lin discusses updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.
Conclusion:
Overall, the patients tolerated idecabtagene vicleucel (ide-cel; bb2121) well. As patients also received lymphodepletion chemotherapy, low blood count was a common adverse effect. However, this toxicity is typically resolved within the first 3 months following the infusion of CAR T-cell therapy
ASH 2020: Abstract 131 (https://ash.confex.com/ash/2020/webprogram/Paper134324.html)
Yi Lin, MD
Dr. Yi Lin is an assistant professor of medicine and oncology, Mayo Clinic.